Quantcast
Last updated on April 16, 2014 at 8:29 EDT

Latest Rosiglitazone Stories

2012-02-28 14:00:00

CRESSKILL, N.J., Feb. 28, 2012 /PRNewswire/ -- In January 2012, GlaxoSmithKline ("GSK") the United Kingdom's largest pharmaceutical company agreed to resolve more than 20,000 cases alleging their diabetes drug Avandia causes heart attacks. Meanwhile, the plaintiffs' attorneys have not been compensated for their out-of-pocket expenses incurred in pursuing these meritorious cases. RD Legal Funding, LLC ("RD Legal") a leading lawsuit settlement funding company, is available to provide qualified...

2012-01-04 08:00:00

Ennis & Ennis, P.A. Provides an Update on the Actos Litigation (PRWEB) January 04, 2012 On December 28, 2011, the U.S. District Court for the Western District of Louisiana consented to the assignment of all federal Actos cases to Honorable Rebecca F. Doherty. As a result, more than 100 lawsuits alleging plaintiffs developed bladder cancer while or after taking Actos will be transferred to the Western District of Louisiana at this time. “I have no doubt this number will increase...

2011-12-27 15:45:00

The law firm of Hissey Kientz, LLP is announcing the launch of its new Crestor website, Crestor Side Effects Lawyers (http://www.crestorsideeffectslawyers.com/). Recent studies have linked Crestor to a number of serious and possibly deadly side effects, including cardiomyopathy, kidney problems and diabetes. Austin, Texas (PRWEB) December 27, 2011 The law firm of Hissey Kientz, LLP is announcing the launch of its new Crestor website, Crestor Side Effects Lawyers...

2011-11-10 08:00:00

Judge Appoints Mediator to Avandia Product Liability Cases and Establishes a Time Limit in which The Cases Must Be Resolved Or They Will Begin Trials, Explains Ennis & Ennis, P.A. (PRWEB) November 10, 2011 Bloomberg Businessweek is reporting U.S. District Judge Cynthia Rufe pushed GlaxoSmithKline (GSK) and the Plaintiffs yesterday to resolve most of the remaining Avandia diabetes medication patient lawsuits by appointing a mediator to preside over settlement negotiations for an...

2011-11-06 08:00:00

Ennis & Ennis, P.A. explains the potential âœBig Pharmaâ settlement. (PRWEB) November 06, 2011 British pharmaceutical company, GlaxoSmithKline (GSK), agreed to pay the US government $3 billion to settle criminal and civil investigations, reports Ennis & Ennis, P.A. If approved, the federal settlement will be the largest settlement for GSK, which is accused of illegally pushing its drugs. The claims against GSK include illegal marketing of...

2011-11-06 08:00:00

According to recent statistics, approximately 30 million Americans have been diagnosed with diabetes and close to 79 million are pre-diabetic. It is a lesser-known fact that between 2004 and 2009, more than 500,000 adverse reactions among people taking anti-diabetic drugs were added to an official U.S. Food and Drug Administration database. James Christopher Dean, an experienced defective drug Attorney, has released a new Actos website, http://www.LawyerforActos.com, with his concern of...

2011-10-13 21:15:00

Gilman Law LLP has over 30 years of experience in complex litigation and class actions involving serious defective drugs. If you or someone you know suffered any adverse side effects of Actos http://www.actos-bladdercancerlawsuits.com, such as bladder cancer or heart disease, or believe you were harmed in any way by taking Actos, you may have a claim for recovery. Bonita Springs, FL, (PRWEB) October 13, 2011 Gilman Law LLP, a leading national law firm, announces that it is now accepting...

2011-09-23 07:00:00

Ennis & Ennis, P.A. Explains that States with a Statute of Limitations of More Than One Year for Product Liability Cases May Still Have Time to File Claims Arising from the Use of Avandia (PRWEB) September 23, 2011 U.S. District Judge Cynthia M. Rufe, the presiding judge on the federal Avandia litigation cases, denied GlaxoSmithKlineâs Statute of Limitations Motion to Dismiss. GlaxoSmithKline (GSK), the manufacturer of Avandia, filed a Motion to Dismiss over 60 lawsuits,...

2011-09-09 14:38:40

Researchers from Dana-Farber Cancer Institute in Boston and the Scripps Research Institute in Jupiter, Fla., report they have created prototype drugs having powerful anti-diabetic effects, yet apparently free — at least in mice — of dangerous side effects plaguing some current diabetes medications. The researchers say that their “proof-of-principle” findings could lead to safer medications for Type 2 diabetes, which affects more than 25 million children and adults...

2011-09-05 11:23:24

Research offers hope for better treatments for diabetes patients In a joint study, scientists from The Scripps Research Institute and Harvard University's Dana-Farber Cancer Institute have established a new class of anti-diabetic compound that targets a unique molecular switch. The finding paves the way for the development of anti-diabetic therapeutics with minimal adverse side effects plaguing currently available drugs such as Avandia (rosiglitazone), scheduled to be removed from...